Among 135 patients receiving first-line nivolumab/ipilimumab, 57 received second-line therapy, and 41 received ...
A survey of multiple transplant centers found a lack of consistent use of comprehensive screening for chronic GVHD; lead ...
Experts weigh continuous vs time‑limited CLL therapy, compare acalabrutinib and zanubrutinib, and debate when pirtobrutinib ...
The FDA has granted fast track designation to safusidenib, an oral IDH1 inhibitor, based on durable phase 2 J201 study ...
The FDA has granted breakthrough therapy designation and fast track designation to 68Ga-NYM096, an investigational PET ...
Agentic AI taps electronic medical records to flag timely oncology trial candidates, fit workflow, cut clinician burden, and ...
Agentic AI in oncology distills evidence, molecular data, and guidelines to aid therapy decisions, promising smarter, context ...
Although he typically prefers to minimize time spent in the hospital and has an hour-long commute to the academic center, he understands that CAR T-cell therapy requires treatment at a specialized ...
CMS’s survey-based ASP–33.4% rate would reduce Part B drug spend (~$5.1B) and beneficiary cost-sharing ($1.15B in 2027), with ...
Andrew Evens, DO, and Joanna Rhodes, MD, on CLL's transformation, CAR T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across New Jersey.
Among the evidence cited is the 5-year follow-up of the ICE3 trial, a single-arm, multicenter study of cryoablation without ...
FDA fast track designation was granted for ETX-19477 in BRCA-mutated HR+/HER2– unresectable or metastatic breast cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results